louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06076369: Differentiation of Tubular Adenoma and Colonic Innominate Groove Under EC Endoscopy
Official title: Differentiation of Tubular Adenoma IIIL Duct Opening and Colonic Innominate Groove Under EC Endoscopy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Endocytoscopy
Keywords: tubular adenoma
IIIL duct opening
colonic innominate groove
Lead sponsor: Jilin University
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Cases of colorectal polyps discovered in our hospital and undergoing EC endoscopic examination.

Brief summary: This study is to analyze the characteristics of the IIIL opening of the duct in tubular adenoma and the colonic innominate groove under EC endoscopy, in order to improve the ability to tell lesions and the colonic innominate groove under EC endoscopy (Endocytoscopy).

Detailed description: This is a prospective cohort study. The recruitment time for all participants will be 4 months. The tubular adenoma group and the colonic innominate groove group will be paired in a 1:2 ratio, with 32 lesions of tubular adenoma and 64 adjacent innominate groove. It is expected that there will be 32 cases and a total of 96 observation subjects. Analyze and compare the characteristics of the opening of the IIIL duct in tubular adenomas and the colonic innominate groove under EC endoscopy, in order to summarize and differentiate them.

Eligibility criteria: Inclusion Criteria:

* Cases of colorectal polyps discovered in our hospital and undergoing EC endoscopic examination.

Exclusion Criteria:

* 1.Suffering from hereditary polyposis or inflammatory bowel disease, severe intestinal inflammation, or difficulty recognizing normal intestinal mucosa;

  2. History of methylene blue allergy;

  3. Patients who have participated or are currently participating in other clinical trials within the first 4 weeks of enrollment;

Primary outcomes:
measure: Proportion of opening length to field of view
timeFrame: 10 minutes after the observation of Endocytoscopy
Secondary outcomes:
measure: Observation of anatomical location
timeFrame: 10 minutes after the observation of Endocytoscopy
Other outcomes:
measure: Morphology of IIIL type glandular opening and unnamed sulcus opening
timeFrame: 10 minutes after the observation of Endocytoscopy
measure: Distribution characteristics of glandular opening
timeFrame: 10 minutes after the observation of Endocytoscopy
Locations:
city: Chang chun
country: China
facility: the First Hospital of Jilin University
state: Ji Lin
Study officials:
References:
Clinical trial NCT02631369: Measuring Cyclotorsion on Scanning Laser Ophthalmoscopy (SLO)-Fundus Photographs
Official title: Measuring Cyclotorsion on Scanning Laser Ophthalmoscopy (SLO)-Fundus Photographs Using the Integrated Algorithm by Heidelberg Spectralis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trochlear Nerve Diseases
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2015-12-16
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Pre-Study: Evaluation of the inter- and intrarater reliability of the integrated algorithm by Heidelberg Spectralis for measuring cyclotorsion on SLO-fundus fotographs, and assessment of the influence of measuring with or without eye tracker.

Study: Comparison of cyclotorsion measurements in patients with forth nerve palsy and in healthy controls on SLO-fundus fotographs using the integrated algorithm by Heidelberg Spectralis


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years old
* best corrected visual acuity ≥ 0.8

Exclusion Criteria:

* strabismus except for forth nerve palsy
* previous strabismus surgery
* monocle
* best corrected visual acuity ≤ 0.6
* hyperopia or myopia \> 6dpt

Primary outcomes:
measure: pre-study: reliability of repeated measurements of excyclotorsion in degrees on SLO-fundus fotographs
timeFrame: 3 months
measure: study: excyclotorsion in degrees on SLO-fundus fotographs
timeFrame: 12 months
Secondary outcomes:
measure: study: excyclotorsion in degrees on tangent screen, double maddox and fundus photographs
timeFrame: 12 months
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Dept of Ophthalmology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Dept of Ophthalmology
name: Ghislaine L Traber, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lengwiler F, Rappoport D, Jaggi GP, Landau K, Traber GL. Reliability of Cyclotorsion measurements using Scanning Laser Ophthalmoscopy imaging in healthy subjects: the CySLO study. Br J Ophthalmol. 2018 Apr;102(4):535-538. doi: 10.1136/bjophthalmol-2017-310396. Epub 2017 Aug 1.
Clinical trial NCT04340869: Treatment of Dentin Hypersensitivity Using Different Desensitizing Agents
Official title: The Effect of Using Two Desensitizing Agents Alone and In Combination on Dentin Permeability and Hypersensitivity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dentin Sensitivity
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2020-04-10
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment of Dentin Hypersensitivity Using Theobromine , Remin Pro , and Combination of Both Materials


Eligibility criteria: Inclusion Criteria:

* Patients that aged 18-50 years.
* Patients in good general health.
* Patients that have accessible teeth demonstrating signs of sensitivity.

Exclusion Criteria:

* • Any chronic debilitating disease that could influence study outcomes.

  * Partial dentures, orthodontic appliances, implants or restorations in a poor state of repair that could influence study outcomes.
  * Intolerance or hypersensitivity to the study desensitizing agents or their ingredients.
  * Desensitising treatment or tooth bleaching within 8 weeks of screening.
  * Daily use of medications that might influence the perception of pain.(

Primary outcomes:
measure: Visual analogue scale pain score
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar University , Faculty of Dental medicine for Girls
Study officials:
References:
Clinical trial NCT00005069: Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
Official title: Phase II Trial of Arsenic Trioxide (NSC #706363) in Patients With Advanced Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Kidney Cancer
Keywords: stage IV renal cell cancer
recurrent renal cell cancer
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2004-05-26
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have metastatic kidney cancer.

Detailed description: OBJECTIVES: I. Evaluate the efficacy of arsenic trioxide in patients with metastatic renal cell cancer. II. Determine the safety of this regimen in this patient population.

OUTLINE: Patients receive arsenic trioxide IV over 1-4 hours daily for 5 days. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for at least 1 month.

PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19 months.

Eligibility criteria: DISEASE CHARACTERISTICS: Histologically confirmed metastatic renal cell cancer Bidimensionally measurable disease No brain metastases

PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life expectancy: Greater than 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin normal ALT or AST no greater than 2.5 times upper limit of normal (ULN) Renal: Creatinine no greater than 1.5 times ULN (no greater than 1.95 mg/dL at MSKCC) Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 4 months after study No other prior malignancy unless curatively treated and disease free for the past 5 years and considered low risk for recurrence

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy and recovered No concurrent biologic therapy Chemotherapy: At least 4 weeks since prior cytotoxic chemotherapy and recovered No other concurrent cytotoxic chemotherapy Endocrine therapy: At least 4 weeks since prior hormonal therapy and recovered No concurrent hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: At least 4 weeks since prior major surgery

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Robert J. Motzer, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06480669: Impact of Intermittent Fasting and Mediterranean Diet on the Physical Health of the Elderly
Official title: Impact of Intermittent Fasting and Mediterranean Diet on the Physical Health of the Elderly: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Hypertension
Dyslipidemias
Obesity
Lead sponsor: Universidad de Zaragoza
Sponsor class: OTHER
First posted: 2024-06-28
Enrollment: 17
Sex: ALL
Minimum age (years): 61
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The prevalence of chronic diseases is increasing globally. In recent years, intermittent fasting has emerged as an effective dietary pattern against some of the most common chronic diseases in the elderly, alongside the Mediterranean diet.

The objective was to determine whether a 12-hour daily intermittent fasting regimen combined with a Mediterranean diet can improve analytical and anthropometric values in the elderly.

A total of 17 individuals of both sexes, over 60 years old, autonomous, and with preserved cognitive capacity participated. They were randomly divided into two groups: 8 people in the intervention group performed intermittent fasting along with a Mediterranean diet, and 9 in the control group adopted only a Mediterranean diet. The intervention lasted 3 months, with measurements taken at the beginning and end of the intervention.


Eligibility criteria: Inclusion Criteria:

* Over 60 years of age.
* Belong to the Bombarda health centre.
* Preserved cognitive capacity.
* Autonomy for basic and instrumental activities of daily living.
* Ability to follow a TRF and/or adopt a Mediterranean dietary pattern.

Exclusion Criteria:

* Underweight (BMI \<18.5).
* Serious or chronic uncontrolled disease.
* Specific treatment that could alter blood and/or anthropometric values.
* Poorly controlled type 1 or type 2 insulin-dependent diabetes mellitus.
* Present or past episode of eating disorder (ED).
* High alcohol consumption.

Primary outcomes:
measure: Biochemical values (mg/dL)
timeFrame: 12 weeks
measure: Blood Pressure (mmHg)
timeFrame: 12 weeks
measure: Anthropometric values (kg)
timeFrame: 12 weeks
measure: Anthropometric values (cm)
timeFrame: 12 weeks
measure: Anthropometric values (kg/m^2)
timeFrame: 12 weeks
measure: Anthropometric index (numerical rating scale)
timeFrame: 12 weeks
measure: Biochemical values (IU/L)
timeFrame: 12 weeks
measure: Biochemical values (mg/L)
timeFrame: 12 weeks
measure: Biochemical values (µg/L)
timeFrame: 12 weeks
measure: Biochemical values (µg/dL)
timeFrame: 12 weeks
measure: Biochemical values (g/dL)
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Zaragoza
country: Spain
facility: University of Zaragoza
Study officials:
References:
Clinical trial NCT01170169: Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions
Official title: A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study to Compare Omeprazole 40 mg DR Capsules Dr. Reddy's Laboratories Ltd.,With Prilosec® 40 mg Merck & Co.Inc., USA Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Dr. Reddy's Laboratories Limited
Sponsor class: INDUSTRY
First posted: 2010-07-27
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study examines the bioequivalence of Dr. Reddy's Omeprazole delayed release capsules under fasting condition.

Detailed description: This is a randomized, two-treatment, two-period, two-sequence, single dose, crossover bioequivalence study to compare Omeprazole 40 mg Delayed Release Capsules (Dr.Reddy's Laboratories Ltd.,) with Prilosec® 40 mg (Omeprazole Delayed Release Capsules (manufactured by Merck \& Co., Inc., USA) in 44 healthy, adult, human subjects under fasting conditions.

Eligibility criteria: Inclusion Criteria:

* Subjects who provided written informed consent.
* Subjects who were healthy within 18-45 years of age, weighing at least 50 kg.
* Body mass index of ≥ 18 kglm2 and ≤ 25 kg/m2, with body weight not less than 50 kg.
* Subjects with normal health as determined by medical history and physical examination performed within 15 days prior to the commencement of the study (dosing in period-I).
* Subjects with normal ECG, chest X-ray (PA view) and vital signs.
* Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.

Test product, dose, mode of administration and batch number

Primary outcomes:
measure: Bioequivalence based on Cmax and AUC parameters
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Vimta Labs Limited, 142, IDA, Phase-II, Cherlapally, Hyderabad - India-500 051
name: Majoj K Bose
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02229669: Coronally Advanced Flap With Two Different Techniques for the Treatment of Multiple Gingival Recessions
Official title: Coronally Advanced Flap With Two Different Techniques for the Treatment of Multiple Gingival Recessions: A Split-mouth RCT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gingival Diseases
Lead sponsor: Paulista University
Sponsor class: OTHER
First posted: 2014-09-01
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study compared the clinical outcomes of coronally advanced flap using two different surgical strategies in the treatment of multiple gingival recessions.

Detailed description: The objective of this split-mouth, randomized controlled trial was to compare the clinical outcomes of coronally advanced flap (CAF) using two different surgical strategies in the treatment of multiple gingival recessions. Recessions were randomly treated according to a split-mouth design by means of: CAF with oblique interdental incisions (OBL technique) or CAF with horizontal interdental incisions (HOR technique). Marginal gingival recession (REC), clinical attachment level (CAL), pocket probing depth (PPD), height of keratinized tissue (HKT) and thickness of keratinized tissue (TKT) were measured at baseline, 3 and 6 months after treatment. Patient-centered outcomes concerning morbidity and improvement in the esthetic appearance were recorded using a Visual Analogue Scale (VAS).

Eligibility criteria: Inclusion Criteria:

* Systemically healthy subjects
* Patients should have bilateral Class I and II MGRs (Miller 1985) in maxillary tooth (at least three recession-type defects affecting adjacent teeth in each side of the maxilla).
* At least 20 teeth and no sites with attachment loss and probing pocket depth (PPD) \> 3 mm.
* Full-mouth plaque and bleeding on probing of \< 20%.
* Involved tooth should present tooth vitality, absence of caries, restorations or extensive non-carious cervical lesion.

Exclusion Criteria:

* History of smoking.
* Antimicrobial and anti-inflammatory therapies in the previous 2 months.
* Previous mucogingival surgery at the region to be treated
* Systemic conditions that could affect tissue healing (e.g. diabetes).
* Use of orthodontic appliances.

Primary outcomes:
measure: Change from baseline in Marginal gingival recession to 6 months
timeFrame: baseline, and at 3 and 6 months post-surgery
Secondary outcomes:
measure: height of keratinized tissue
timeFrame: Baseline, 3 and 6 months
measure: thickness of keratinized tissue
timeFrame: baseline, 3 and 6 months
measure: Clinical attachment level
timeFrame: baseline, 3 and 6 months
measure: Probing deph
timeFrame: baseline, 3 and 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Paulista University
name: Suzana Pimentel, PHD
role: PRINCIPAL_INVESTIGATOR
affiliation: Paulista University
name: Guilherme Barrella, MS
role: STUDY_CHAIR
References:
Clinical trial NCT05162469: A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors
Official title: A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-1909 Injection in Patients With Advanced Malignant Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Advanced Malignant Cancer
Lead sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-12-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Dose escalation (non randomized， 6 arms); Dose-expansion and efficacy-expansion(non-randomized,1-3 arms)
Primary purpose: TREATMENT

Brief summary: This is an, open-label, multi-center, three-part phase I trial to evaluate the safety, pharmacokinetics and immunogenicity of SHR-1909 and preliminary anti-tumor efficacy of SHR-1909 in advanced malignant cancer.


Eligibility criteria: Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
* Patients must have cytologically or histologically confirmed advanced malignant tumor, and must have failed standard treatment;
* Toxicities caused by prior anti-tumor treatments must have resolved to CTCAE Grade ≤ 1 prior to the first dose (except for alopecia or hypothyroidism treated with hormone replacement therapy or diabetes controlled with insulin);
* Adequate organ function.

Exclusion Criteria:

* With CNS infiltration, or ascites requiring paracentesis or symptomatic pleural effusion;
* Received prior CAR T-cell therapy;
* Received allogeneic hematopoietic stem cell transplantation within 3 months prior to the start of study treatment, or with acute/chronic graft versus host disease;
* With active infection or fever of unknown origin (\> 38.5 °C).

Primary outcomes:
measure: MTD of SHR-1909
timeFrame: From Day 1 to 4 weeks
measure: RP2D of SHR-1909
timeFrame: From Day 1 to 90 days after last dose
Secondary outcomes:
measure: Adverse Events
timeFrame: 90 days after the last dose
measure: Objective Response Rate (ORR)
timeFrame: Up to approximately 2 years
measure: Progression-Free Survival (PFS)
timeFrame: Up to approximately 2 years
Other outcomes:
Locations:
city: Changchun
country: China
facility: Jilin Cancer Hospital
state: Jilin
Study officials:
References:
Clinical trial NCT04973969: Follicular Challenge Test to Predict Response to GnRH Agonist Triggering
Official title: Follicular Challenge Test to Predict Response to GnRH Agonist Triggering
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility, Female
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2021-07-22
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 41
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: GnRH agonist triggering is used during ART in order to reduce the risk of OHSS. Some studies described that in up to 5% of the cycles triggered with GnRH agonist, a lack of respone or suboptimal response was displayed.

The investigators aim to asses the possibility to predict the respone to ovulation triggering by the response to decapeptyl in the follicular phase of the same cycle.

Detailed description: The investigators will use Decapeptyl on day 2 of menstruation followed by antagonist protocol.

Hormonal proflie including E2, P, LH, FSH will be measured. LH surge and the rest of the hormonal profile will be compared to day after ovulation triggering.

Eligibility criteria: Inclusion Criteria:

* patients that undergo fertility preservation

  * patients planned to freeze embryos due to PGT or surrogacy --patients at high risk for OHSS

Exclusion Criteria:

* Poor ovarian response
* known hypothalamic- pituitary dysfunction

Primary outcomes:
measure: The response to GnRH triggering
timeFrame: One treatment cycle (each cycle is 28 days) for each participant (up to 28 days).
Secondary outcomes:
Other outcomes:
Locations:
city: Tzrifin
country: Israel
facility: Shamir medical center
Study officials:
affiliation: Asaf Harofe Medical Center
name: Sarit Avraham, Dr
role: PRINCIPAL_INVESTIGATOR
References: